President NAKAMURA Yusuke
Since the National Institute of Biomedical Innovation and the National Institute of Health and Nutrition merged in 2015 to form the National Institutes of Biomedical Innovation, Health, and Nutrition, a six-center system, which includes the Center for Drug Design Research, has been established based on the first medium- to long-term plan. The National Institute of Health and Nutrition was located in Tokyo, but it relocated to Kento (the cities of Suita and Settsu) in Osaka by the end of March, 2023, establishing a foundation for the combined institutes to cooperate more with the local community and to work on projects to extend healthy life expectancy.
Our second 7-years medium- to long-term plan started in 2022. The plan addresses various issues with an "era of a 100-year lifespan" in mind. Key terms in the plan are "individualization and optimization." In the future, optimal guidance and medical care tailored to each individual will need to be provided, both to maintain and improve health through diet and exercise and to treat illnesses. We would like to further accelerate our research, and thus benefit society, through the use of advanced AI analytics in drug discovery and nutritional science.
Based on extensive collaboration with two hospitals in Osaka, the Osaka International Cancer Institute and the Osaka Women's and Children's Hospital, the National Institutes of Biomedical Innovation, Health, and Nutrition has begun working with patients and medical facilities to cure diseases that are currently incurable. Intractable diseases and rare diseases are difficult for private companies to work on. Fulfilling its purpose as a national research facility, the National Institutes of Biomedical Innovation, Health, and Nutrition has made research and development targeting those diseases one of its priorities.
In addition, the National Institutes of Biomedical Innovation, Health, and Nutrition will further focus on pharmaceuticals and health and nutrition together in order to maximize the benefits of the merger of the two institutes. In areas where pharmaceuticals and health and nutrition overlap, we are exploring new possibilities, such as in our research on intestinal bacteria.
We will contribute to extending healthy longevity by developing innovative drug discovery technologies, conducting food and nutrition research and surveys, and generating and implementing creative basic research ideas. We cordially ask for your continued support.